ロード中...
Novel Short-Course Therapy and Morphism Mapping for Clinical Pulmonary Mycobacterium kansasii
Standard therapy (isoniazid, rifampin, and ethambutol), with or without a macrolide, for pulmonary Mycobacterium kansasii lasts more than a year. Therefore, shorter treatment duration regimens are required. We used data from 32 Taiwanese patients treated with standard therapy who were followed using...
保存先:
| 出版年: | Antimicrob Agents Chemother |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society for Microbiology
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8092872/ https://ncbi.nlm.nih.gov/pubmed/33558291 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01553-20 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|